We used the NCI-H2291 cell line to assess the response of G12F-mutant NSCLC cells to the G12C-specific inhibitor, and employed CRISPR/Cas9 technology to knock-in KRAS c.35G>T into the NCI-H358_28D5 NSCLC cell line (Fig. 2A), a heterozygous KRAS G12C cell line carrying four G12C and two WT alleles (Fig. S3A). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.